Selective Tetrahydrofuran Nav1.8 Modulators With a Wider Therapeutic Window
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing Nav inhibitors for neuropathic pain lack isoform selectivity, leading to a poor therapeutic window and potential adverse events.
Innovation Solution
Development of a method to synthesize substituted tetrahydrofuran modulators that selectively target Nav1.8 sodium channels, utilizing a series of chemical reactions to convert starting compounds into potent and selective Nav1.8 blockers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective Nav inhibitors are used to treat neuropathic pain, then pain relief is achieved, but adverse events occur due to lack of isoform selectivity
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features (substituted tetrahydrofuran core structure with particular substituents at defined positions) that confer selective affinity for Nav1.8 channels. This structural specificity ensures the drug acts locally on the target isoform rather than broadly on all Nav channels, thereby improving therapeutic window and reducing adverse events associated with non-selective inhibition
2Object-affected harmful factors
If selective Nav1.8 blockers are developed, then adverse effects are minimized, but synthesis complexity increases
Solution Approach 1:
The patent employs segmentation by dividing the synthesis into modular stages: preparing substituted tetrahydrofuran core structures, installing specific substituents at defined positions, and final compound assembly. This stepwise approach with isolated intermediates (formulas II-V and VII-XXI) manages synthesis complexity while achieving the selective structure necessary to minimize adverse effects
Solution Approach 2:
The patent applies preliminary action by pre-synthesizing and characterizing key intermediates (substituted tetrahydrofuran compounds with specific stereochemistry and substitution patterns) before final assembly. This advance preparation of building blocks with controlled purity and stereochemistry simplifies the overall process while ensuring the selective properties needed to reduce adverse effects
Data Source
AI summary
Provided in this application is a process for making Compound I (I) and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels. Processes for making various intermediate products, and suitable salts thereof, are also provided.